SG11202108140SA - Anti-bag2 antibody and methods of treating cancer - Google Patents
Anti-bag2 antibody and methods of treating cancerInfo
- Publication number
- SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA
- Authority
- SG
- Singapore
- Prior art keywords
- bag2
- antibody
- methods
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190016359A KR102241558B1 (en) | 2019-02-12 | 2019-02-12 | An antibody or antigen-binding fragment thereof specifically binding to BAG2 polypeptide or fragment thereof |
KR1020190016347A KR102172541B1 (en) | 2019-02-12 | 2019-02-12 | A Composition comprising antibody specifically binding to BAG2 for the diagnosis of cancer and method using the same |
PCT/IB2020/051136 WO2020165794A1 (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108140SA true SG11202108140SA (en) | 2021-08-30 |
Family
ID=72044199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108140SA SG11202108140SA (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Country Status (10)
Country | Link |
---|---|
US (2) | US20230183324A1 (en) |
EP (2) | EP3924382A4 (en) |
JP (2) | JP2022521706A (en) |
CN (2) | CN114269779A (en) |
AU (1) | AU2020222326A1 (en) |
BR (1) | BR112021015940A2 (en) |
CA (1) | CA3129748A1 (en) |
MX (1) | MX2021009690A (en) |
SG (1) | SG11202108140SA (en) |
WO (2) | WO2020165797A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007516693A (en) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Compositions and methods for the treatment and diagnosis of cancer |
US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
EP2142670A1 (en) * | 2007-04-05 | 2010-01-13 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of breast cancer |
EP2250282A4 (en) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | Methods of diagnosing and treating parp-mediated diseases |
US20100204055A1 (en) * | 2008-12-05 | 2010-08-12 | Bonner-Ferraby Phoebe W | Autoantibody detection systems and methods |
KR102039624B1 (en) * | 2017-03-03 | 2019-11-01 | 재단법인 차세대융합기술연구원 | A method of screening materials for inhibition of interaction between BAG2 and Cathepsin B |
KR102230314B1 (en) * | 2017-10-24 | 2021-03-22 | 주식회사 메드팩토 | A method for the diagnosis of cancer using blood |
-
2020
- 2020-02-12 AU AU2020222326A patent/AU2020222326A1/en active Pending
- 2020-02-12 JP JP2021547311A patent/JP2022521706A/en active Pending
- 2020-02-12 SG SG11202108140SA patent/SG11202108140SA/en unknown
- 2020-02-12 US US16/758,930 patent/US20230183324A1/en active Pending
- 2020-02-12 EP EP20755764.6A patent/EP3924382A4/en active Pending
- 2020-02-12 WO PCT/IB2020/051139 patent/WO2020165797A1/en unknown
- 2020-02-12 JP JP2021547308A patent/JP2022525843A/en active Pending
- 2020-02-12 CN CN202080027907.0A patent/CN114269779A/en active Pending
- 2020-02-12 US US16/758,934 patent/US20230194534A1/en active Pending
- 2020-02-12 CA CA3129748A patent/CA3129748A1/en active Pending
- 2020-02-12 CN CN202080028383.7A patent/CN114761803A/en active Pending
- 2020-02-12 MX MX2021009690A patent/MX2021009690A/en unknown
- 2020-02-12 BR BR112021015940-1A patent/BR112021015940A2/en unknown
- 2020-02-12 WO PCT/IB2020/051136 patent/WO2020165794A1/en unknown
- 2020-02-12 EP EP20755277.9A patent/EP3938788A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230183324A1 (en) | 2023-06-15 |
CN114269779A (en) | 2022-04-01 |
CA3129748A1 (en) | 2020-08-20 |
WO2020165794A1 (en) | 2020-08-20 |
EP3938788A1 (en) | 2022-01-19 |
BR112021015940A2 (en) | 2021-10-05 |
EP3938788A4 (en) | 2023-01-04 |
EP3924382A1 (en) | 2021-12-22 |
JP2022521706A (en) | 2022-04-12 |
US20230194534A1 (en) | 2023-06-22 |
JP2022525843A (en) | 2022-05-20 |
MX2021009690A (en) | 2021-10-01 |
CN114761803A (en) | 2022-07-15 |
WO2020165797A1 (en) | 2020-08-20 |
AU2020222326A1 (en) | 2021-08-19 |
EP3924382A4 (en) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL289663A (en) | Claudin18 antibodies and methods of treating cancer | |
IL267803A (en) | Methods of treating cancer with anti-tim-3 antibodies | |
ZA202004735B (en) | Anti-pd-1 antibodies and methods of treatment | |
IL273196A (en) | Claudin6 antibodies and methods of treating cancer | |
IL266990A (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
IL281441B (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
IL288086A (en) | Methods and materials for treating cancer | |
SG11202010793UA (en) | Methods of treating cancer | |
IL282478A (en) | Materials and methods for treating cancer | |
SG11202111672RA (en) | Cancer associated antibody compositions and methods of use | |
SG11202107017TA (en) | Methods of treating cancer | |
IL285352A (en) | Anti-nme antibody and method of treating cancer or cancer metastasis | |
EP3759125A4 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
IL281600A (en) | Methods of treating cancer | |
IL277981A (en) | Methods of treating cancer | |
IL276203A (en) | Compositions and methods of treating cancer | |
IL287687A (en) | Methods of treating cancer with an anti-pd-l1 antibody | |
IL289811A (en) | Method of treating cancer | |
ZA202105583B (en) | Methods of diagnosing and treating cervical cancer | |
EP4061421A4 (en) | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors | |
SG11202108140SA (en) | Anti-bag2 antibody and methods of treating cancer | |
EP3585819A4 (en) | Antibody constructs and methods of treating cancer | |
IL307556A (en) | Methods of treating cancer with anti-tigit antibodies | |
IL283912A (en) | Methods of treating cancer using platanoside and isomers thereof |